SLC5A2 and kidney disorder: Additionally, compared to completed SGLT2 inhibitor cardiovascular outcome trials (Zinman et al., 2015; Neal et al., 2017; Wiviott et al., 2019), the CREDENCE trial enrolled people at high risk for kidney failure and had a primary outcome of major renal end points and demonstrated that patients with T2DM and kidney disease who received canagliflozin had a lower risk of kidney failure and cardiovascular events than those who received a placebo at a median follow-up of 2.62 years (Perkovic et al., 2019).